Opinion
Video
Author(s):
Focusing on metastatic prostate cancer, 2 experts have a comprehensive discussion on treatment options for patients with metastatic prostate cancer.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Phase 3 trial launches of ifinatamab deruxtecan vs chemotherapy in mCRPC
Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025
FDA does not approve talazoparib plus enzalutamide for non-HRR gene mutated mCRPC
Dr. Murphy on increasing diversity in cancer clinical trials
Adding cetrelimab to niraparib maintenance shows benefit in aggressive variant prostate cancer
Phase 1 study launches for novel CYP11A1 inhibitor for mCRPC
FDA approves integrated sacral neuromodulation system for urinary urge incontinence
Money Matters: A financial guide to approaching retirement
Study to evaluate impact of ArteraAI on clinical decision-making for prostate cancer